Alliance Foundation Trials, Llc.
Clinical trials sponsored by Alliance Foundation Trials, Llc., explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New hope for recurrent endometrial cancer: personalized combo therapy tested Results expected Oct 2026 (estimated)
- New combo aims to stall advanced lung cancer Results expected Nov 2026 (estimated)
- New drug cocktail shows promise for myeloma patients ineligible for transplant Results expected Dec 2026 (estimated)
-
New drug cocktail shows early promise for Hard-to-Treat myeloma
Disease control CompletedThis early-phase study tested a combination of three drugs—ibrutinib, lenalidomide, and dexamethasone—in 14 people with multiple myeloma that had come back or stopped responding to prior treatments. The main goal was to find safe doses and watch for side effects. Results help gui…
Phase 1 • Sponsor: Alliance Foundation Trials, LLC. • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC
-
New combo therapy aims to stall returning prostate cancer
Disease control CompletedThis phase 3 study tested whether adding apalutamide (Erleada) to standard hormone therapy (LHRH analogues) can delay cancer progression in men whose prostate cancer has returned after surgery. 504 men with rapidly rising PSA levels took part. The goal was to see if the combinati…
Phase 3 • Sponsor: Alliance Foundation Trials, LLC. • Aim: Disease control
Last updated Jun 27, 2026 08:05 UTC
-
Which prostate cancer drug is kinder to your brain? new study aims to find out
Knowledge-focused CompletedThis study looked at how two prostate cancer drugs, darolutamide and enzalutamide, affect thinking and memory in men with advanced prostate cancer. About 111 men took one of the two drugs and completed computer-based cognitive tests over time. The goal was to see if one drug caus…
Phase 2 • Sponsor: Alliance Foundation Trials, LLC. • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC